INZY Inozyme Pharma Inc

Price (delayed)

$5.665

Market cap

$350.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$376.12M

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in ...

Highlights
The quick ratio has grown by 29% YoY and by 4.4% from the previous quarter
INZY's EPS is up by 13% year-on-year
The equity has declined by 15% since the previous quarter but it is up by 15% year-on-year
The company's debt has surged by 75% YoY
The company's net income fell by 14% YoY and by 8% QoQ

Key stats

What are the main financial stats of INZY
Market
Shares outstanding
61.86M
Market cap
$350.41M
Enterprise value
$376.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$72.45M
EBITDA
-$71.14M
Free cash flow
-$77.59M
Per share
EPS
-$1.37
Free cash flow per share
-$1.26
Book value per share
$1.92
Revenue per share
$0
TBVPS
$2.86
Balance sheet
Total assets
$176.94M
Total liabilities
$58.11M
Debt
$46.64M
Equity
$118.84M
Working capital
$161.92M
Liquidity
Debt to equity
0.39
Current ratio
14.05
Quick ratio
13.42
Net debt/EBITDA
-0.36
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42%
Return on equity
-58.7%
Return on invested capital
-41.4%
Return on capital employed
-44%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INZY stock price

How has the Inozyme Pharma stock price performed over time
Intraday
2.26%
1 week
-1.82%
1 month
27.3%
1 year
-19.07%
YTD
32.98%
QTD
27.02%

Financial performance

How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.62M
Net income
-$77.11M
Gross margin
N/A
Net margin
N/A
INZY's operating income is down by 16% year-on-year and by 8% since the previous quarter
The company's net income fell by 14% YoY and by 8% QoQ

Growth

What is Inozyme Pharma's growth rate over time

Valuation

What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
2.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is up by 13% year-on-year
The price to book (P/B) is 20% higher than the last 4 quarters average of 2.4
The equity has declined by 15% since the previous quarter but it is up by 15% year-on-year

Efficiency

How efficient is Inozyme Pharma business performance
The company's return on invested capital rose by 38% YoY and by 6% QoQ
INZY's ROE is down by 10% year-on-year and by 5% since the previous quarter
The company's return on assets rose by 7% YoY but it fell by 3.2% QoQ

Dividends

What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INZY.

Financial health

How did Inozyme Pharma financials performed over time
The total liabilities has soared by 51% YoY but it fell by 3.7% QoQ
Inozyme Pharma's current ratio has increased by 32% YoY and by 5% from the previous quarter
The company's debt is 61% lower than its equity
The company's debt has surged by 75% YoY
The debt to equity has soared by 50% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.